The HIV/HCV-Coinfected Patient and New Treatment Options

被引：6

作者：

Vachon, Marie-Louise C. ^{[1
,2
]}

Dieterich, Douglas T. ^{[1
]}

机构：

[1] Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA

[2] Mt Sinai Sch Med, Div Infect Dis, New York, NY 10029 USA

来源：

CLINICS IN LIVER DISEASE | 2011年 / 15卷 / 03期

关键词：

HIV; Hepatitis C; Coinfection; Treatment; Direct-acting antivirals; CHRONIC HEPATITIS-C; INTERFERON PLUS RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; HIV-INFECTED PATIENTS; HUMAN-IMMUNODEFICIENCY-VIRUS; INSULIN-RESISTANCE; LIVER FIBROSIS; PEGYLATED INTERFERON-ALPHA-2B; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITORS;

D O I：

10.1016/j.cld.2011.05.006

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Hepatitis C (HCV) treatment is on the cusp of change with the approval of the first direct-acting antivirals: telaprevir and boceprevir. Drug-drug interactions with HIV antiretrovirals, increased toxicity, and rapid selection of HCV-resistant mutants are among the treatment complexities expected in this difficult-to-treat population. Until the current standard of care changes, focus should be on strategies to optimize management of HIV/HCV-coinfected patients with currently available options. This article reviews the latest predictive factors of response to HCV treatment with the current standard of care in HIV-coinfected patients, and new treatment options.

引用

页码：585 / +

页数：14

共 50 条

[31] Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women
Lo Re, Vincent, III
Lynn, Kenneth
Stumm, Emily R.
Long, Jin
Nezamzadeh, Melissa S.
Baker, Joshua F.
Hoofnagle, Andrew N.
Kapalko, Angela J.
Mounzer, Karam
Zemel, Babette S.
Tebas, Pablo
Kostman, Jay R.
Leonard, Mary B.
[J]. JOURNAL OF INFECTIOUS DISEASES, 2015, 212 (06): : 924 - 933
[32] Characteristics of B-Cell Lymphomas in HIV/HCV-Coinfected Patients
Terrier, Benjamin
Costagliola, Dominique
Besson, Caroline
[J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 67 (02) : E86 - E87
[33] HIV and HCV coinfected haemophilia patients: what are the best options of orthopaedic treatment?
Rodriguez-Merchan, EC
[J]. HAEMOPHILIA, 2006, 12 : 90 - 101
[34] The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals
de Mendoza, C
Soriano, V
[J]. ANTIVIRAL THERAPY, 2005, 10 : M109 - M115
[35] Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals
Hopkins, S
Lambourne, J
Farrell, G
McCullagh, L
Hennessy, M
Clarke, S
Mulcahy, F
Bergin, C
[J]. HIV MEDICINE, 2006, 7 (04) : 248 - 254
[36] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
Perez-Latorre, Leire
Sanchez-Conde, Matilde
Miralles, Pilar
Carlos Lopez, Juan
Parras, Francisco
Tejerina, Francisco
Aldamiz-Echevarria, Teresa
Carrero, Ana
Diez, Cristina
Ramirez, Margarita
Gutierrez, Isabel
Maria Bellon, Jose
Banares, Rafael
Berenguer, Juan
[J]. BMC INFECTIOUS DISEASES, 2018, 18
[37] Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients
Laguno, M
Milinkovic, A
de Lazzari, E
Murillas, J
Martínez, E
Blanco, JL
Loncá, M
Biglia, A
Leon, A
García, M
Larrousse, M
García, F
Miró, JM
Gatell, JM
Mallolas, J
[J]. ANTIVIRAL THERAPY, 2005, 10 (03) : 423 - 429
[38] Genetic Polymorphisms Associated with Liver Disease Progression in HIV/HCV-Coinfected Patients
Medrano, Luz M.
Jimenez-Sousa, Maria A.
Fernandez-Rodriguez, Amanda
Resino, Salvador
[J]. AIDS REVIEWS, 2017, 19 (01) : 3 - 15
[39] Understanding the Mechanisms of Fibrogenesis in HIV/HCV-Coinfected Patients: Implications for Clinical Practice
Sacchi, Paolo
Cima, Serena
Zuccaro, Valentina
Columpsi, Paola
Sarda, Cristina
Mariani, Marcello
Puoti, Massimo
Bruno, Raffaele
[J]. AIDS REVIEWS, 2015, 17 (03) : 159 - 170
[40] Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype
Caudai, C
Pianese, M
Zacchini, F
Toti, M
Zazzi, M
Valensin, PE
[J]. JOURNAL OF CLINICAL VIROLOGY, 2005, 32 (02) : 151 - 155

← 1 2 3 4 5 →